-
Atletico go third with comfortable win at Girona
-
Schwarz breaks World Cup duck with Alta Badia giant slalom victory
-
Salah unaffected by Liverpool turmoil ahead of AFCON opener - Egypt coach
-
Goggia eases her pain with World Cup super-G win as Vonn takes third
-
Goggia wins World Cup super-G as Vonn takes third
-
Cambodia says Thai border clashes displace over half a million
-
Kremlin denies three-way US-Ukraine-Russia talks in preparation
-
Williamson says 'series by series' call on New Zealand Test future
-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
West Indies 43-0, need 419 more to win after Conway joins elite
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
How Can Gum Disease Lead to Tooth Loss in Kyle, TX?
-
West Indies 420 all out to trail New Zealand by 155
-
Arteta tells leaders Arsenal to 'learn' while winning
-
Honour to match idol Ronaldo's Real Madrid calendar year goal record: Mbappe
-
Dupont helps Toulouse bounce back in Top 14 after turbulent week
-
Mbappe matches Ronaldo record as Real Madrid beat Sevilla
-
Gyokeres ends drought to gift Arsenal top spot for Christmas
-
Arsenal stay top despite Man City win, Liverpool beat nine-man Spurs
-
US intercepts oil tanker off coast of Venezuela
-
PSG cruise past fifth-tier Fontenay in French Cup
-
Isak injury leaves Slot counting cost of Liverpool win at Spurs
-
Juve beat Roma to close in on Serie A leaders Inter
-
US intercepts oil tanker off coast of Venezuela: US media
-
Zelensky says US must pile pressure on Russia to end war
-
Haaland sends Man City top, Liverpool beat nine-man Spurs
-
Epstein victims, lawmakers criticize partial release and redactions
-
Leverkusen beat Leipzig to move third in Bundesliga
-
Lakers guard Smart fined $35,000 for swearing at refs
-
Liverpool sink nine-man Spurs but Isak limps off after rare goal
Independent Evaluation Confirms Breakthrough Performance of BioLargo's Cellinity Battery Technology for Grid-Scale Energy Storage
WESTMINSTER, CALIFORNIA / ACCESS Newswire / June 18, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that a third-party evaluation has confirmed key advantages for its Cellinity battery technology's use in grid-scale battery energy storage applications.
The evaluation was conducted by U.S. BESS Corporation (www.usbesscorp.com), an expert provider of advanced energy storage solutions for critical infrastructure applications spanning utilities, defense, microgrids, and heavy industry.
U.S. BESS senior technical staff performed an examination of Cellinity's design and assembly protocols, inspection of testing infrastructure, review of data from test results, and an assessment of methodologies used for performance characterization, concluding that the following performance characteristics exclusive of any auxiliary systems are supported by their observations and are reasonably representative of the current Cellinity cell's demonstrated behavior:
Open circuit voltage: > 4.2 V
Operating temperature range: from 120°C to 250°C
Energy density: > 500 Wh/kg (calculated based on active material)
Power density: > 500 mW/cm3 (maximum observed value of 1579 W/kg at 230°C)
Charge capacity: Cell can be charged to 100% of theoretical capacity
Charge/discharge efficiency: ~100%
Energy efficiency: 95% at 230°C; 87% at 120°C
Self-discharge: No measurable self-discharge observed over test durations
Thermal cycling durability: Performance unaffected after repeated cycling
U.S. BESS Corp further concluded that it is reasonable to claim that a) the cell would not experience any thermal runaway, b) materials of construction are commonly available and can be domestically sourced, c) the cell does not contain any rare earth elements, and d) cell components are fully recyclable.
A Market Ready for Disruption
The global demand for grid-scale energy storage is rapidly growing to meet the rising loads driven by artificial intelligence, decarbonization mandates, and accelerated adoption of renewables. In 2024 alone, the U.S. Energy Information Administration (www.eia.gov) reported a 66% increase in U.S. battery energy storage capacity. While lithium-ion batteries currently dominate the market, they present known challenges: fire risks from thermal runaway, efficiency losses over time, and sourcing constraints related to rare and critical minerals.
BioLargo's Cellinity battery technology (www.biolargoenergy.com) overcomes these limitations by leveraging novel materials and architecture to deliver both exceptional thermal performance and operational efficiencywithout relying on rare earth elements.
Validation Supports Commercial Pathway
The U.S. BESS report concludes: "Based on our inspection and the evidence provided, U.S. BESS finds that the Cellinity Cell demonstrates a sufficient performance profile, with strong indications of high thermal stability, efficiency, energy and power density, and material sustainability, to suggest further investment in testing and commercialization. These attributes position this technology as a potential solution for critical gaps in grid-scale energy storage markets."
Randall Moore, Chief Technology Officer at BioLargo Energy Technologies, Inc., commented, "Our work to scale up the cell design, refine manufacturing techniques, and integrate cells into a functional module for commercial scale testing is underway."
CEO, Dennis P. Calvert commented, "We do not know of any long duration energy storage technology that can match Cellinity's technical claims for cost effective performance and safety. This third-party evaluation is an important piece of the puzzle for our business plan to bring Cellinity to the world through manufacturing joint ventures. We have several of these in development with potential partners and look forward to sharing more intel about those soon."
About U.S. BESS Corp
U.S. BESS Corp is a U.S.-based company that provides energy storage solutions for a wide range of applications, including utilities, industrial needs, microgrids and defense. With decades of combined experience in battery engineering, microgrid deployment, system-level integration, and manufacturing, the company's leadership team is uniquely qualified in the battery energy storage system industry. U.S. BESS is creating the most advanced and secure battery management system and building the largest domestic battery supply in the USA.
U.S. BESS Corp Contact Information
Mark Hagedorn
CEO, U.S. BESS Corp.
503-720-9569
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
BioLargo Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
M.Robinson--AT